BCO Conference Coverage: SABCS 2022
Every December, the San Antonio Breast Cancer Symposium brings together clinicians, researchers, and advocates to discuss the latest breast cancer study results. We're proud to present our coverage below.
***Stay tuned to this thread as more coverage is added!***
Comments
-
Metastatic breast cancer patient advocates Christine Hodgdon and Stephanie Walker explain why the viewpoints of people living with metastatic breast cancer need to be incorporated into research.
A number of issues affecting people diagnosed with metastatic breast cancer, including financial toxicity, support, and early palliative care, were discussed at an educational session on the first day of the 2022 San Antonio Breast Cancer Symposium. Metastatic patient advocates Christine Hodgdon and Stephanie Walker talked about what they want researchers and clinicians to know about day-to-day life with metastatic disease.
Listen to the episode to hear Christine and Stephanie discuss:
- why the patient perspective is important
- if and how the patient perspective is taken into account as new treatments are developed
- what they hope happens as a result of their participation in the session
0 -
Dr. Virginia Kaklamani explains the latest results from the EMERALD trial comparing elacestrant to the standard of care.
Doctors are looking for new treatment options for people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy and a CDK4/6 inhibitor. Dr. Virginia Kaklamani is part of the team investigating elacestrant, an oral medicine, to see if offers more benefits than Faslodex (chemical name: fulvestrant), which is the current standard of care.
Listen to the podcast to hear Dr. Kaklamani explain:
- the type of medicine elacestrant is and how it works
- why it's important that elacestrant showed benefits for breast cancers with an ESR1 mutation
- when we might hear if elacestrant is approved by the U.S. Food and Drug Administration (FDA)
0 -
Podcast: Enhertu Offers Better Overall Survival Than Kadcyla for Metastatic HER2-Positive Breast Cancer
Dec 9, 2022Dr. Sara Hurvitz discusses new overall survival results from the DESTINY-Breast03 study.
2021 results from the DESTINY-Breast03 study showed that Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) more than doubled the 12-month progression-free survival rate compared to Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated.
At the 2022 San Antonio Breast Cancer Symposium, Dr. Sara Hurvitz presented new overall survival results, showing that Enhertu also improves overall survival compared to Kadcyla.
Listen to the episode to hear Dr. Hurvitz explain:
- overall survival and progression-free survival results
- severe side effects of Enhertu
- how the researchers managed any severe lung problems that developed in people receiving Enhertu
0 -
Podcast: What I Get From Breastcancer.org Meetups
Dec 10, 2022Breastcancer.org Community Member Vanessa Onsurez talks about her diagnosis, #ThisIsMBC, and Meetups.
Vanessa Onsurez, who was diagnosed with metastatic breast cancer in 2021, explains the #ThisIsMBC project at the 2022 San Antonio Breast Cancer Symposium and the benefits she gets from the Breastcancer.org Virtual Community Meetups.
Listen to the episode to hear Vanessa discuss:
- how she got involved in #ThisIsMBC
- how she found Breastcancer.org and what she's learned in the Meetups
- what she wants to leave as her legacy
0 -
Podcast: 2022 SABCS Key Take-Aways
Dec 13, 2022Dr. Stephanie Graff explains the most interesting research presented at the 2022 San Antonio Breast Cancer Symposium.
The 2022 San Antonio Breast Cancer Symposium featured five days of research presentations, educational sessions, and posters. The amount of research presented can be overwhelming, so we asked Dr. Stephanie Graff to break down the key take-aways for people who've been diagnosed with breast cancer.
Listen to the episode to hear Dr. Graff explain:
- updated results from the monarchE study
- updated results from the TAILORx study
- results from the RIGHT Choice trial
- her thoughts on whether HER2-low breast cancer is a distinct subtype
0 -
Podcast: GRASP: Helping Advocates Understand Research, Helping Researchers Understand Patients
Dec 14, 2022Patient advocates and researchers who are part of GRASP talk about what they've learned from the program.
GRASP – Guiding Researchers and Advocates to Scientific Partnership – connects patients, doctors, and researchers to exchange ideas and learn from each other. At the 2022 San Antonio Breast Cancer Symposium, we asked advocates and researchers who are part of the program what they have learned from the program.
Listen to the episode to learn about:
- plans for launching a Spanish version of the program
- how the mentor aspect of the program works
- how the program helps researchers refine their programs
0 -
Dr. Nicholas Turner explains research looking at capivasertib, a new targeted therapy medicine.
Researchers are always looking for new treatments for advanced-stage breast cancer. Dr. Nicholas Turner explains the results of the CAPitello-291 trial, looking capivasertib, an experimental targeted therapy medicine, in combination with Faslodex (chemical name: fulvestrant) as a treatment for advanced-stage, hormone receptor-positive, HER2-negative breast cancer that has become resistant to the aromatase inhibitors.
Listen to the episode to hear Dr. Turner explain:
- how capivasertib works
- the results of the CAPitello-291 trial
- how capivasertib worked on cancers previously treated with a CDK4/6 inhibitor
0